JPMA Proposes New Value-Based Pricing System for Innovative Meds, No Price Cut in Patent Period

JPMA President Yasushi Okada The Japan Pharmaceutical Manufacturers Association (JPMA) unveiled its fresh proposal on August 30, calling for introducing a new value-based pricing system for innovative medicines and excluding patent-protected drugs from the current market price-based NHI price revisions...read more